CD274 and non-small cell lung carcinoma: In another retrospective study, the prognostic and predictive role of pre-treatment NLR was evaluated in a large cohort of stage III NSCLC patients treated with definitive chemoradiation and adjuvant immunotherapy with anti-PD-L1 agent durvalumab.